White Flag Raised: UniQure Gives Up On Glybera, But Not Gene Therapies
Executive Summary
UniQure will not seek marketing authorization renewal for Glybera in the EU before it expires in October, but the company does not see the product's commercial failure as a sign that the market won't accept gene therapies or their high price tags.
You may also be interested in...
Gene Therapy Manufacturing Hurdle: Sponsors Unwilling To Share ‘Secret Sauce’
US FDA’s Peter Marks says companies are not exchanging information about adenoviral factors, which is probably slowing down the field. He describes NIH's plans for a bespoke gene therapy consortium for vector generation and continued efforts for regulatory harmonization.
Individualized Therapeutics Could Get Boost From NIH Platform Gene Therapy Pilot
Experience and data from the study, which will use the same vector platform to deliver different transgenes for different diseases, could feed into the US FDA’s efforts to establish a public-private partnership to enable manufacturing of gene therapies for ultra-rare diseases.
10 Drug Launch Flops Of The Decade
The view from 2020: Scrip looks back over the last decade at the drug launches that defied expectations – for the worse.
Need a specific report? 1000+ reports available
Buy Reports